Antiva Biosciences: Funding, Investors & Team (Sep 2026)
Antiva Biosciences, situated in South San Francisco, specializes in creating innovative, targeted medical solutions to cure illnesses that emerge as a result of HPV infection. It originated in 2012 as Hera Therapeutics, created by Dr. Karl Hostetler at The University of California San Diego.
Antiva Biosciences has raised $84.0M across 2 funding rounds on record, the most recent a Series E of $53.0M announced in Apr 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Antiva Biosciences Company Profile and Key Stats
Latest funding round on record: Apr 2023.
Antiva Biosciences Funding Rounds
Antiva Biosciences raised $31.0M in a Series D announced in Nov 2021.
1.4 years later, a Series E of $53.0M was announced in Apr 2023.
Antiva Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Antiva Biosciences Funding Compared to Other Biotechnology Startups
Antiva Biosciences' latest round of $53.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Antiva Biosciences in Biotechnology and Del Mar
Companies Similar to Antiva Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Antiva Biosciences Funding FAQs
What does Antiva Biosciences do?
Antiva Biosciences, situated in South San Francisco, specializes in creating innovative, targeted medical solutions to cure illnesses that emerge as a result of HPV infection. It originated in 2012 as Hera Therapeutics, created by Dr. Karl Hostetler at The University of California San Diego.
How much funding has Antiva Biosciences raised?
Antiva Biosciences has raised $84.0M across 2 rounds on record. The most recent is a Series E of $53.0M announced in Apr 2023.
When did Antiva Biosciences last raise funding?
Antiva Biosciences' most recent funding round on record is a Series E of $53.0M, announced in Apr 2023.
Who founded Antiva Biosciences?
FundedIQ lists Karl Hostetler (Founder) at Antiva Biosciences.
Who is the CEO of Antiva Biosciences?
Gail Maderis is listed as CEO at Antiva Biosciences.
Where is Antiva Biosciences headquartered?
Antiva Biosciences is based in Del Mar, California, United States.
How many employees does Antiva Biosciences have?
Antiva Biosciences is in the 11-50 employee band.
How does Antiva Biosciences' funding compare to other Biotechnology startups?
Antiva Biosciences' latest round of $53.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Antiva Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Antiva Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.